JP2006503081A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503081A5
JP2006503081A5 JP2004543799A JP2004543799A JP2006503081A5 JP 2006503081 A5 JP2006503081 A5 JP 2006503081A5 JP 2004543799 A JP2004543799 A JP 2004543799A JP 2004543799 A JP2004543799 A JP 2004543799A JP 2006503081 A5 JP2006503081 A5 JP 2006503081A5
Authority
JP
Japan
Prior art keywords
oxazol
amine
phenyl
methoxyphenyl
ethylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004543799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/033317 external-priority patent/WO2004032882A2/en
Publication of JP2006503081A publication Critical patent/JP2006503081A/ja
Publication of JP2006503081A5 publication Critical patent/JP2006503081A5/ja
Pending legal-status Critical Current

Links

JP2004543799A 2002-10-10 2003-10-10 化学化合物 Pending JP2006503081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41754802P 2002-10-10 2002-10-10
PCT/US2003/033317 WO2004032882A2 (en) 2002-10-10 2003-10-10 Chemical compounds

Publications (2)

Publication Number Publication Date
JP2006503081A JP2006503081A (ja) 2006-01-26
JP2006503081A5 true JP2006503081A5 (enExample) 2006-11-24

Family

ID=32094036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004543799A Pending JP2006503081A (ja) 2002-10-10 2003-10-10 化学化合物

Country Status (5)

Country Link
US (1) US7189712B2 (enExample)
EP (1) EP1551813A4 (enExample)
JP (1) JP2006503081A (enExample)
AU (1) AU2003287178A1 (enExample)
WO (1) WO2004032882A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) * 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
US20070249628A1 (en) * 2004-05-18 2007-10-25 Alain Moussy Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons
NZ588896A (en) * 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
MX2008015226A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
US8227470B2 (en) 2007-01-12 2012-07-24 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
MX2009011199A (es) 2007-04-16 2010-03-17 Hutchison Medipharma Entpr Ltd Derivados de pirimidina.
WO2009071448A1 (en) * 2007-12-05 2009-06-11 Basf Se Pyridylmethyl-sulfonamide compounds
AR069802A1 (es) 2007-12-20 2010-02-17 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
US8268874B2 (en) * 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
EP2550266B1 (en) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2012166463A2 (en) 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
CN102757400B (zh) * 2012-07-18 2014-08-06 贵州大学 2,5-取代基噁唑类衍生物及其应用
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101713027B1 (ko) * 2015-12-23 2017-03-07 한국원자력의학원 페닐옥사졸계 유도체를 포함하는 암 예방 또는 치료용 조성물
KR101948555B1 (ko) 2017-08-03 2019-02-15 한국원자력의학원 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US11472781B2 (en) * 2018-02-21 2022-10-18 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
MX2021009570A (es) 2019-02-15 2021-09-08 Bristol Myers Squibb Co Compuestos biciclicos sustituidos como moduladores del receptor de farnesoide x.
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
KR20250144817A (ko) * 2024-03-27 2025-10-13 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021707A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU764479B2 (en) * 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US20090048301A1 (en) * 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents

Similar Documents

Publication Publication Date Title
RU2489426C2 (ru) Производные аминопиразола
JP2010533158A5 (enExample)
JP2007516173A5 (enExample)
JP2019517455A5 (enExample)
JP2015533157A5 (enExample)
JP2018535999A5 (enExample)
JP2009537543A5 (enExample)
JP2013519680A5 (enExample)
JP2007530690A5 (enExample)
JP2005538955A5 (enExample)
IL303196A (en) Heteroaryl-substituted pyridines and methods of use
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
RU2012116207A (ru) Производные индола в качестве модуляторов crac
JP2006503019A5 (enExample)
JP2023506642A5 (enExample)
RU2006133909A (ru) Производные азабицикло {3. 1. 0}гексана, применимые в качестве модуляторов допаминовых рецепторов d3
JP2007523208A5 (enExample)
RU2004121029A (ru) Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1)
JP2010540452A5 (enExample)
JP2006524686A5 (enExample)
JP2009525340A5 (enExample)
JP2018507234A5 (enExample)
JP2017538750A5 (enExample)
RU2016111138A (ru) Гетероциклические соединения и способы их применения
JP2020500192A5 (enExample)